JP2013502442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013502442A5 JP2013502442A5 JP2012525830A JP2012525830A JP2013502442A5 JP 2013502442 A5 JP2013502442 A5 JP 2013502442A5 JP 2012525830 A JP2012525830 A JP 2012525830A JP 2012525830 A JP2012525830 A JP 2012525830A JP 2013502442 A5 JP2013502442 A5 JP 2013502442A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- tetrahydroxy
- cholan
- bile
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23675009P | 2009-08-25 | 2009-08-25 | |
| US61/236,750 | 2009-08-25 | ||
| PCT/CA2010/001338 WO2011022838A1 (en) | 2009-08-25 | 2010-08-25 | Polyhydroxylated bile acids for treatment of biliary disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013502442A JP2013502442A (ja) | 2013-01-24 |
| JP2013502442A5 true JP2013502442A5 (enExample) | 2013-10-10 |
| JP5909774B2 JP5909774B2 (ja) | 2016-04-27 |
Family
ID=43627124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012525830A Active JP5909774B2 (ja) | 2009-08-25 | 2010-08-25 | 胆道疾患を治療するためのポリヒドロキシル化胆汁酸 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP2470553B1 (enExample) |
| JP (1) | JP5909774B2 (enExample) |
| CN (1) | CN102712672B (enExample) |
| AU (1) | AU2010286253A1 (enExample) |
| BR (1) | BR112012004284B8 (enExample) |
| SG (1) | SG178562A1 (enExample) |
| WO (1) | WO2011022838A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2659455T3 (es) | 2011-09-19 | 2018-03-15 | ETH Zürich | Moduladores del ROR gamma para tratar complicaciones de diabetes II |
| SG10201909122QA (en) * | 2011-10-28 | 2019-11-28 | Lumena Pharmaceuticals Inc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| US20140323412A1 (en) | 2011-10-28 | 2014-10-30 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease |
| SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
| US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
| BR112015012312A2 (pt) * | 2012-11-28 | 2017-07-11 | Intercept Pharmaceuticals Inc | método de tratamento, redução do risco, prevenção ou alívio de uma afecção ou doença pulmonar em um sujeito; método de redução ou supressão de inflamação no pulmão em um sujeito; e método de promoção de reparo pulmonar em um sujeito |
| EP2781217A1 (en) * | 2013-03-18 | 2014-09-24 | ETH Zurich | ROR gamma modulators |
| WO2015017813A2 (en) * | 2013-08-01 | 2015-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the farnesoid x receptor and uses in medicine |
| CN104523703A (zh) * | 2014-12-24 | 2015-04-22 | 聂飚 | 一种游离脂肪酸转运蛋白小分子抑制物的应用 |
| WO2020041673A1 (en) | 2018-08-23 | 2020-02-27 | President And Fellows Of Harvard College | Compositions and methods related to cholic acid-7-sulfate as a treatment for diabetes |
| EP3890745B1 (en) | 2018-12-04 | 2025-11-19 | President and Fellows of Harvard College | Synthetic derivatives of cholic acid 7-sulfate and uses thereof |
| KR102204406B1 (ko) * | 2019-01-23 | 2021-01-18 | (주)샤페론 | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 염증성 장질환 예방 또는 치료용 조성물 |
| CN109762043B (zh) * | 2019-03-06 | 2020-07-24 | 华南理工大学 | 鹅去氧胆酸及其制备方法 |
| WO2020231776A1 (en) | 2019-05-10 | 2020-11-19 | President And Fellows Of Harvard College | Small molecule modulators of gut bacterial bile acid metabolism |
| CN116925168A (zh) | 2019-08-23 | 2023-10-24 | 深圳云合医药科技合伙企业(有限合伙) | 胆汁酸衍生物及其组合物和应用 |
| CN110548037B (zh) * | 2019-09-24 | 2023-06-02 | 江西天元药业有限公司 | 精制熊胆粉及其增强体质治疗和预防肿瘤和癌症的用途 |
| CN113024624B (zh) * | 2019-12-25 | 2024-09-10 | 上海科胜药物研发有限公司 | 一种去氧胆酸的合成方法 |
| WO2022233398A1 (en) | 2021-05-04 | 2022-11-10 | Kostner Pharma Gmbh | COMPOUNDS FOR REDUCING LIPOPROTEIN(a) |
| CN115337312B (zh) * | 2022-08-19 | 2025-06-03 | 金熊药业(珠海横琴)有限公司 | 胆酸复合物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS632932A (ja) * | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US7303768B2 (en) * | 1998-07-24 | 2007-12-04 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| WO2000004875A2 (en) * | 1998-07-24 | 2000-02-03 | Seo Hong Yoo | Preparation of aqueous clear solution dosage forms with bile acids |
| WO2006116815A1 (en) * | 2005-05-02 | 2006-11-09 | Vanadis Bioscience Ltd | Composition for the control of cholesterol levels |
| US20090074895A1 (en) * | 2005-05-02 | 2009-03-19 | Vanadis Bioscience Ltd | Composition and uses thereof |
| WO2009105897A1 (en) * | 2008-02-26 | 2009-09-03 | British Columbia Cancer Agency Branch | Polyhydroxylated bile acids for treatment of biliary disorders |
-
2010
- 2010-08-25 CN CN201080048314.9A patent/CN102712672B/zh active Active
- 2010-08-25 SG SG2012013132A patent/SG178562A1/en unknown
- 2010-08-25 AU AU2010286253A patent/AU2010286253A1/en not_active Abandoned
- 2010-08-25 BR BR112012004284A patent/BR112012004284B8/pt active IP Right Grant
- 2010-08-25 WO PCT/CA2010/001338 patent/WO2011022838A1/en not_active Ceased
- 2010-08-25 JP JP2012525830A patent/JP5909774B2/ja active Active
- 2010-08-25 EP EP10811080.0A patent/EP2470553B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013502442A5 (enExample) | ||
| WO2010121128A3 (en) | Compositions and methods for treating or inhibiting liver injury | |
| IL272718A (en) | 11-hydroxyl-derivatives of bile acids and amino acid conjugates thereof as farnesoid x receptor modulators | |
| JP2019507781A5 (enExample) | ||
| WO2008057420A3 (en) | Extended triterpene derivatives | |
| SG10201909122QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| SG10201903512SA (en) | Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases | |
| WO2007101873A3 (en) | Betulonic acid esters and betulinic acid polyalkylene-glycol derivatives for the treatment of viral infection and cancer | |
| JP2017515854A5 (enExample) | ||
| JP2009530413A5 (enExample) | ||
| JP2015512953A5 (enExample) | ||
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| NZ586751A (en) | Use of CDDO methyl ester (methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate) for the treatment of renal diseases and for improving kigney function | |
| WO2009028457A1 (ja) | 非アルコール性脂肪肝炎治療薬 | |
| JP2013509411A5 (enExample) | ||
| WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
| JP2016530279A5 (enExample) | ||
| JP2020504129A (ja) | 非アルコール性脂肪性肝炎（ｎａｓｈ）および肝線維症のための併用療法 | |
| JP2012511510A5 (enExample) | ||
| RU2019110779A (ru) | Новые схемы введения агонистов fxr | |
| EA201001100A1 (ru) | Фармацевтическая композиция на основе гепатопротектора и пребиотика, получение и применение | |
| AU2005331734B2 (en) | Use of 24-nor-UDCA | |
| Buchanan-Peart et al. | Novel therapies in primary biliary cholangitis: what is in the pipeline? | |
| RU2015126505A (ru) | Применение и способы лечения заболеваний и патологических состояний печени | |
| JP2008533079A5 (enExample) |